CellaVision delivers 1,000th digital cell morphology system to Southampton General Hospital, England
(Thomson Reuters ONE) -
CellaVision, which develops and sells products for routine analysis of blood and
other body fluids in health care, has delivered its 1,000th CellaVision® DM
analyzer. The achievement confirms the company's position as a market leading
supplier, and is an important milestone in the company's ten-year sales history.
The order from Southampton General Hospital came in July through the distributor
Sysmex Europe, CellaVision's partner in Europe for 10 years, and was delivered
to the customer site this week.
"We are proud of this significant achievement to have placed 1,000 systems
globally since our sales began in 2001," stated Yvonne Mårtensson, CEO of
CellaVision. "With customers in more than 40 countries, we are recognized for
product excellence and adding value to the lab. This strengthens us in our goal
to become the global standard for digital cell morphology in hematology. Many
thanks to all our customers and partners who have helped us to build our market
through confidence in CellaVision and our products.
The global market for CellaVision's products is large, and CellaVision is
working in many countries, both through strong partners as well as its own
subsidiaries. CellaVision's target group is hospitals with more than 200 beds
and commercial laboratories that at present perform analyses manually using a
microscope. The demand for CellaVision's products is strong and is due to
increased efficiency and quality requirements in the healthcare market,
particularly in Europe and North America. Growing staff shortages in laboratory
operations make CellaVision's automated products a necessity in many labs.
Brief history
CellaVision was founded in 1994 to develop automated microscopic analysis. The
idea came from the then medical student Christer Fahraeus, now one of Sweden's
best known entrepreneurs. 1997, CellaVision recruited its first employees and as
early as in 2000 the first analyzer was launched in Europe. The year after
CellaVision found its first customer, the University Hospital in Malmo, and the
instrument was cleared by the FDA. Since then it has strengthened its product
portfolio, grown its customer base globally and since 2007 CellaVision continues
expanding, profitably. 2010 turnover was 132 million SEK with North America
accounting for 50% of sales, Europe for 40% and the rest of the world for 10%.
For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 708 33 77 82. E-mail:yvonne.martensson(at)cellavision.com
About CellaVision
CellaVision is an innovative, global medical technology company that develops
and sells best-in-class systems for the routine analysis of blood and other body
fluids. These analyses often provide critical results used in the diagnosis of a
variety of illnesses such as infection and cancer. CellaVision's products reduce
manual laboratory work, standardize results and support an efficient laboratory
workflow. The company has leading-edge expertise in digital image analysis,
artificial intelligence and automated microscopy. In 2010, net sales were 132
MSEK and sales continue to grow with the target to increase by at least 15 % per
year over an economic cycle. CellaVision has its head office in Lund, Sweden,
and subsidiaries in the US, Canada and Japan. The company share is listed on
Nasdaq OMX Stockholm, Small Cap. Read more atwww.cellavision.com.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: CellaVision AB via Thomson Reuters ONE
[HUG#1543374]
Unternehmensinformation / Kurzprofil:
Datum: 01.09.2011 - 10:08 Uhr
Sprache: Deutsch
News-ID 61426
Anzahl Zeichen: 4276
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 218 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CellaVision delivers 1,000th digital cell morphology system to Southampton General Hospital, England"
steht unter der journalistisch-redaktionellen Verantwortung von
CellaVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
